Lack of Association between (AAT)n Polymorphism of the CNR1 Gene Encoding the Cannabinoid Receptor (CB1) and Patient's Quality of Life

Genes (Basel). 2022 Nov 6;13(11):2046. doi: 10.3390/genes13112046.

Abstract

Genetic factors may predispose persons to decreased pain excitability. One of the interesting modulators affecting pain perception may be polymorphisms of the cannabinoid receptor type 1 (CNR1) gene. In this study, we examined the association between three-nucleotide repeats (AAT) polymorphism located in the 3'UTR non-translational region of CNR1 and the patient's quality of life after total hip arthroplasty. Our study examined the degree of pain sensation, hip function, and the patient's performance at defined intervals after elective hip replacement due to degenerative changes. The study included 198 patients (128 women and 70 men). The average age was 67 years. PCR genotyping assay was used to identify the (AAT)n triplet repeat polymorphism in the CNR1 gene. The (AAT)n repeat number was determined by sequencing using a standard sequencing protocol. Our study found no statistically significant association between the degree of pain, hip function, and the change in the degree of disability and the (AAT)n polymorphism in the CNR1 gene, no statistically significant correlations between clinical symptoms, the patient's age, and the number of AAT repeats, no association between the length of the allele and the degree of pain, hip function, and the change in disability.

Keywords: hip function; microsatellite (AAT)n polymorphism of CNR1 gene; postoperative pain.

MeSH terms

  • Aged
  • Female
  • Genetic Predisposition to Disease*
  • Humans
  • Male
  • Pain
  • Polymorphism, Genetic
  • Quality of Life*
  • Receptor, Cannabinoid, CB1 / genetics
  • Receptors, Cannabinoid

Substances

  • Receptors, Cannabinoid
  • CNR1 protein, human
  • Receptor, Cannabinoid, CB1

Grants and funding

This research received no external funding.